OMERS ADMINISTRATION Corp Purchases 117,775 Shares of Kenvue Inc. $KVUE

Key Points

• OMERS ADMINISTRATION Corp has increased its stake in Kenvue Inc. by 20.6%, owning 689,104 shares valued at approximately $16.5 million after acquiring 117,775 additional shares.
• Kenvue Inc. reported a quarterly EPS of $0.29, exceeding estimates of $0.28, while its revenue decreased 4.0% year-over-year to $3.84 billion.
• The company declared a quarterly dividend of $0.2075 per share, representing a 4.0% yield, an increase from the previous dividend of $0.21.

OMERS ADMINISTRATION Corp boosted its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 20.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 689,104 shares of the company's stock after purchasing an additional 117,775 shares during the quarter. OMERS ADMINISTRATION Corp's holdings in Kenvue were worth $16,525,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in KVUE. Pittenger & Anderson Inc. bought a new stake in Kenvue during the 1st quarter valued at approximately $30,000. TruNorth Capital Management LLC bought a new stake in Kenvue in the 1st quarter worth approximately $36,000. Truvestments Capital LLC bought a new stake in Kenvue in the 1st quarter worth approximately $37,000. Clal Insurance Enterprises Holdings Ltd increased its stake in Kenvue by 378.5% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company's stock worth $39,000 after acquiring an additional 1,287 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich increased its stake in Kenvue by 120.6% in the 1st quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company's stock worth $41,000 after acquiring an additional 929 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Wall Street Analyst Weigh In

KVUE has been the topic of a number of research reports. UBS Group reduced their price objective on Kenvue from $25.00 to $23.00 and set a "neutral" rating on the stock in a research note on Thursday, July 17th. JPMorgan Chase & Co. reduced their price objective on Kenvue from $27.00 to $26.00 and set an "overweight" rating on the stock in a research note on Friday, July 25th. Canaccord Genuity Group reduced their price objective on Kenvue from $29.00 to $26.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Zacks Research raised Kenvue to a "strong sell" rating in a research note on Monday, August 11th. Finally, Royal Bank Of Canada decreased their price target on Kenvue from $24.00 to $22.00 and set a "sector perform" rating on the stock in a report on Friday, August 8th. Five equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Kenvue has an average rating of "Hold" and an average price target of $24.38.

Kenvue Trading Up 0.9%

KVUE traded up $0.18 during trading hours on Monday, reaching $20.72. 10,307,391 shares of the company's stock traded hands, compared to its average volume of 17,119,262. The firm has a 50-day moving average price of $21.46 and a 200 day moving average price of $22.45. The firm has a market capitalization of $39.76 billion, a PE ratio of 27.99, a PEG ratio of 2.97 and a beta of 0.83. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 52-week low of $19.75 and a 52-week high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The business had revenue of $3.84 billion during the quarter, compared to the consensus estimate of $3.94 billion. During the same period last year, the company earned $0.32 earnings per share. The business's revenue for the quarter was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, sell-side analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were given a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 4.0%. This is a positive change from Kenvue's previous quarterly dividend of $0.21. The ex-dividend date was Wednesday, August 13th. Kenvue's dividend payout ratio is 112.16%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.